OMN6 A NOVEL BIOENGINEERED PEPTIDE FOR THE TREATMENT OF MULTIDRUG RESISTANT GRAM NEGATIVE BACTERIA

April 11, 2021

New antimicrobial agents are urgently needed, especially to eliminate multidrug resistant Gram‐ negative bacteria that stand for most antibiotic‐resistant threats. In the following study, we present superior properties of an engineered antimicrobial peptide, OMN6, a 40‐amino acid cyclic peptide based on Cecropin A . . . READ ARTICLE PUBLISHED MARCH 23, 2021

OMN6-a-Novel-Bioengineered-Peptide-for-the-Treatment-of-Multidrug-Resistant-Gram-Negative-Bacteria Download

More To Explore

Omnix Medical Announces Excellent Topline Data from the Phase I Clinical Trial of its Novel Anti-Infective OMN6

OMN6 demonstrates safety and tolerability at clinically significant dose levels JERUSALEM, Israel, May 8th, 2023 — Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for

RECOGNITION AT EUROPEAN INNOVATION COUNCIL’S INVESTOR DAY

We are delighted to announce that Dr. Niv Bachnoff, our Chief Scientific Officer, has won the First Prize for Best Presentation in the Biotech &

STUDY: In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant Acinetobacter baumannii

The rapid worldwide spread of antimicrobial resistance (AMR) underscores the significant need for the development of innovative treatments to fight multidrug-resistant bacteria. Our Scientists at Omnix

Contact Us

Reach US

Made with ❤ by WildWeb

Omnix Medical Ltd. is committed to making its website and all its electronic information easier to use and more accessible for people with disabilities. The company’s website was created and/or updated according to the provisions of the Equal Rights for People with Disabilities Law, 5748-1998, and the delegated legislation stemming from it, and it fully complies with the W3C Web Content Accessibility Guidelines 2.0, AA level.

Omnix Medical Ltd. will continue its efforts to constantly improve the accessibility of its website and information in the belief that it is our collective moral obligation to allow seamless, accessible, and unhindered use also for those of us with disabilities.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No 966627 (OMNIX MEDICAL).